Celltrion USA Signs Express Scripts Deal: FDA-Approved ZYMFENTRA

 


Celltrion USA has just announced a new partnership with Express Scripts, a major pharmacy benefit manager in the United States. This agreement, effective April 4, 2024, will make ZYMFENTRA Preferred Brand Access available on the Express Scripts National Preferred Formulary, benefiting 21.9 million insured lives. Express Scripts will now offer ZYMFENTRA™ (infliximab-dyyb) to plan participants, providing them with access to this FDA-approved treatment option for chronic diseases. This collaboration is a significant step towards improving access to care for millions of patients in need.


More Information : https://www.techdogs.com/tech-news/pr-newswire/celltrion-usa-signs-agreement-with-express-scripts-for-its-therapy-for-autoimmune-diseases-including-the-first-fda-approved-subcutaneous-infliximab-zymfentra

Comments

Popular posts from this blog

Aon Unveils $350M Program for Ukraine Recovery

E&R Engineering Debuts Advanced Solutions at Semicon SEA 2024

Cloud Computing Trends 2025